| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Trials |
Departments of Clinical Oncology [T. W. T. L., S. K. W. H., A. T. C. C., T. S. K. M., W. Y., A. M. Y. T., P. J. J.], Surgery [W-y. L.], Diagnostic Radiology and Organ Imaging [S. C. H. Y.], Anatomical and Cellular Pathology [C-t. L.], and Medicine [N. W. Y. L.], The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, and M. D. Anderson Cancer Center, University of Texas, Houston, Texas 77030-4009 [Y. Z. P.]
The purpose of this Phase II study was to determine the response rate, the toxicity, and the effect on survival of the combination of cisplatin, doxorubicin, 5-fluorouracil, and 
-IFN (PIAF) in advanced unresectable hepatocellular carcinoma. Fifty patients with either unresectable or metastatic disease were treated with PIAF: cisplatin (20 mg/m2 i.v., days 1–4), doxorubicin (40 mg/m2 i.v., day 1), 5-fluorouracil (400 mg/m2 i.v., days 1–4), and -IFN (5 MU/m2 s.c., days 1–4). Treatment was repeated every 3 weeks to a maximum of six cycles. All patients were evaluable for response, toxicity, and survival. As assessed by conventional imaging criteria, there were no complete responses, but 13 patients (26%) had a partial response. Among the 36 patients who had an initially high |ga-fetoprotein level (>500 ng/ml), 15 (42%) had a >50% fall after therapy. Nine patients underwent surgical resection after achieving partial response and, in 4 of these patients, histological examination of the resected specimens revealed no viable tumor cells. All these nine patients are alive, and eight patients remain in complete remission at between 7.6 and 25.8 months at the time of analysis. The overall median survival was 8.9 months. Toxicity was mainly myelosuppression and mucositis. There were two treatment-related deaths due to neutropenic sepsis. PIAF is active in hepatocellular carcinoma despite considerable hematological toxicity. Complete pathological remission is possible with this systemic combination. Apparently, persistent radiological lesions may still represent complete pathological resolution of active disease.
This article has been cited by other articles:
|
|
 |
|
  S. Jelic and On behalf of the ESMO Guidelines Working Group Hepatocellular carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv41 - iv45. [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Chan, F. K.F. Mo, P. J. Johnson, E. P. Hui, B. B.Y. Ma, W. M. Ho, K. C. Lam, A. T.C. Chan, T. S.K. Mok, and W. Yeo New Utility of an Old Marker: Serial {alpha}-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy J. Clin. Oncol., January 20, 2009; 27(3): 446 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ikeda, T. Okusaka, H. Ueno, C. Morizane, Y. Kojima, S. Iwasa, and A. Hagihara Predictive Factors of Outcome and Tumor Response to Systemic Chemotherapy in Patients with Metastatic Hepatocellular Carcinoma Jpn. J. Clin. Oncol., October 1, 2008; 38(10): 675 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. V. Tse, M. Hawkins, G. Lockwood, J. J. Kim, B. Cummings, J. Knox, M. Sherman, and L. A. Dawson Phase I Study of Individualized Stereotactic Body Radiotherapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma J. Clin. Oncol., February 1, 2008; 26(4): 657 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Y. Lau and E. C. H. Lai Salvage Surgery Following Downstaging of Unresectable Hepatocellular Carcinoma A Strategy to Increase Resectability Ann. Surg. Oncol., December 1, 2007; 14(12): 3301 - 3309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. H. O'Neil and A. P. Venook Hepatocellular Carcinoma: The Role of the North American GI Steering Committee Hepatobiliary Task Force and the Advent of Effective Drug Therapy Oncologist, December 1, 2007; 12(12): 1425 - 1432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Alberts, G. J. Gores, G. P. Kim, L. R. Roberts, M. L. Kendrick, C. B. Rosen, S. T. Chari, and J. A. Martenson Treatment Options for Hepatobiliary and Pancreatic Cancer Mayo Clin. Proc., May 1, 2007; 82(5): 628 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Welsh Radiographically Identified Necrosis After 90Y Microsphere Brachytherapy: A New Standard for Oncologic Response Assessment? Am. J. Roentgenol., March 1, 2007; 188(3): 765 - 767. [Full Text] [PDF]
|
|
|
|
|
|
G.-Y. Chau, W.-Y. Lui, S.-H. Tsay, Y. Chao, K.-L. King, and C.-W. Wu Postresectional Adjuvant Intraportal Chemotherapy in Patients with Hepatocellular Carcinoma: A Case-Control Study Ann. Surg. Oncol., October 1, 2006; 13(10): 1329 - 1337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K. Abou-Alfa, L. Schwartz, S. Ricci, D. Amadori, A. Santoro, A. Figer, J. De Greve, J.-Y. Douillard, C. Lathia, B. Schwartz, et al. Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma J. Clin. Oncol., September 10, 2006; 24(26): 4293 - 4300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. X. Zhu Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be? Oncologist, July 1, 2006; 11(7): 790 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. X. Zhu, L. S. Blaszkowsky, D. P. Ryan, J. W. Clark, A. Muzikansky, K. Horgan, S. Sheehan, K. E. Hale, P. C. Enzinger, P. Bhargava, et al. Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma J. Clin. Oncol., April 20, 2006; 24(12): 1898 - 1903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Hellerbrand, M. Muhlbauer, S. Wallner, M. Schuierer, I. Behrmann, F. Bataille, T. Weiss, J. Scholmerich, and A.-K. Bosserhoff Promoter-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma Carcinogenesis, January 1, 2006; 27(1): 64 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Yeo, T. S. Mok, B. Zee, T. W. T. Leung, P. B. S. Lai, W. Y. Lau, J. Koh, F. K. F. Mo, S. C. H. Yu, A. T. Chan, et al. A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon {alpha}-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma J Natl Cancer Inst, October 19, 2005; 97(20): 1532 - 1538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. X. Zhu, C. S. Fuchs, J. W. Clark, A. Muzikansky, K. Taylor, S. Sheehan, K. Tam, E. Yung, M. H. Kulke, and D. P. Ryan A Phase II Study of Epirubicin and Thalidomide in Unresectable or Metastatic Hepatocellular Carcinoma Oncologist, June 1, 2005; 10(6): 392 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kondo, H. Nagano, H. Wada, B. Damdinsuren, H. Yamamoto, N. Hiraoka, H. Eguchi, A. Miyamoto, T. Yamamoto, H. Ota, et al. Combination of IFN-{alpha} and 5-Fluorouracil Induces Apoptosis through IFN-{alpha}/{beta} Receptor in Human Hepatocellular Carcinoma Cells Clin. Cancer Res., February 1, 2005; 11(3): 1277 - 1286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Yeo, K. C. Lam, B. Zee, P. S. K. Chan, F. K. F. Mo, W. M. Ho, W. L. Wong, T. W. T. Leung, A. T. C. Chan, B. Ma, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy Ann. Onc., November 1, 2004; 15(11): 1661 - 1666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Z. Patt, M. M. Hassan, R. D. Lozano, T. D. Brown, J. N. Vauthey, S. A. Curley, and L. M. Ellis Phase II Trial of Systemic Continuous Fluorouracil and Subcutaneous Recombinant Interferon Alfa-2b for Treatment of Hepatocellular Carcinoma J. Clin. Oncol., February 1, 2003; 21(3): 421 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Szklaruk, P. M. Silverman, and C. Charnsangavej Imaging in the Diagnosis, Staging, Treatment, and Surveillance of Hepatocellular Carcinoma Am. J. Roentgenol., February 1, 2003; 180(2): 441 - 454. [Full Text] [PDF]
|
|
|
|
 |
|
 P J Johnson Hepatocellular carcinoma: is current therapy really altering outcome? Gut, October 1, 2002; 51(4): 459 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Z. Patt, M. M. Hassan, R. D. Lozano, K. A. Waugh, A. M. Hoque, A. I. Frome, S. Lahoti, L. Ellis, J. N. Vauthey, S. A. Curley, et al. Phase II Trial of Cisplatin, Interferon {alpha}-2b, Doxorubicin, and 5-Fluorouracil for Biliary Tract Cancer Clin. Cancer Res., November 1, 2001; 7(11): 3375 - 3380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Zhang, M. Chew, E. B. Yang, K. P. Wong, and P. Mack Modulation of Cisplatin Cytotoxicity and Cisplatin-Induced DNA Cross-Links in HepG2 Cells by Regulation of Glutathione-Related Mechanisms Mol. Pharmacol., April 1, 2001; 59(4): 837 - 843. [Abstract] [Full Text]
|
|
|
|
|
|
H. Eguchi, H. Nagano, H. Yamamoto, A. Miyamoto, M. Kondo, K. Dono, S. Nakamori, K. Umeshita, M. Sakon, and M. Monden Augmentation of Antitumor Activity of 5-Fluorouracil by Interferon {{alpha}} Is Associated with Up-Regulation of p27Kip1 in Human Hepatocellular Carcinoma Cells Clin. Cancer Res., July 1, 2000; 6(7): 2881 - 2890. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
